French National Observatory of the Patients With Non-small Cell Lung (NSCLC) and Molecular Testings
1 other identifier
observational
17,664
1 country
133
Brief Summary
The French National Cancer Institute (INCa) support a 28 hospital platforms network for molecular testing of cancer patients. These platforms routinely assess a panel of biomarkers in order to speed up access of French cancer patients to targeted therapies (commercially available or through clinical trials). The objective of the BIOMARKERS-France study is to describe the epidemiological, clinical and molecular characteristics of these patients and their tumors and to assess the impact of these analyzes on their treatment (ie bio-guided therapy) as well as outcomes (response rate, progression free and overall survival).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2012
Shorter than P25 for all trials
133 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2012
CompletedFirst Submitted
Initial submission to the registry
August 1, 2012
CompletedFirst Posted
Study publicly available on registry
October 4, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2013
CompletedJuly 21, 2023
July 1, 2023
1 year
August 1, 2012
July 20, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
EGF-R gene mutation in nationwide cohort
Number of patients with EGF-R gene mutation
1 Year
Secondary Outcomes (5)
K-RAS gene mutation in nationwide cohort
1 year
EML4-ALK translocation in nationwide cohort
1 year
BRAF gene mutation in nationwide cohort
1 year
HER2 gene mutation in nationwide cohort
1 year
PI3K gene mutation in nationwide cohort
1 year
Study Arms (1)
Patients with advanced lung cancer
Patients with advanced lung cancer
Eligibility Criteria
Patients with advanced non-small cell cancer
You may qualify if:
- Advanced Non-small cell lung cancer (NSLC)
- Biomarkers analysis on hospital platforms
You may not qualify if:
- \- Histology other than NSLC
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (133)
Clinique Calabet - Centre de Radiothérapie et d'Oncologie
Agen, France
Clinique Claude Bernard
Albi, France
Clinique de l'Europe
Amiens, France
CHU d'Angers
Angers, France
Hôpital Privé d'Antony
Antony, France
CHIC
Aulnay-sous-Bois, France
Auxerre - CH
Auxerre, 89011, France
CH d'Avignon
Avignon, France
CH de la Côte Basque
Bayonne, France
CHU Besancon - Pneumologie
Besançon, 25000, France
CH de Béziers
Béziers, France
Blois - CH
Blois, 41016, France
CHU Avicenne
Bobigny, France
Hôpital Ambroise Paré - Pneumologie
Boulogne, France
Hôpital Fleyriat
Bourg-en-Bresse, France
Hôpital de Briançon
Briançon, France
CHU Côte de Nâcre
Caen, France
Cahors - CH
Cahors, 46000, France
CH de Cannes
Cannes, France
Chambray Les Tours - Clinique Léonard de Vinci
Chambray-lès-Tours, 37170, France
CH de Chartres Hôpital Louis Pasteur
Chartres, France
Chevilly-Larue - CH
Chevilly-Larue, 94669, France
Hôpital de Cholet - Pneumologie
Cholet, France
Hôpital Percy-Armées - Pneumologie
Clamart, 92140, France
Hôpital Pasteur
Colmar, France
Clinique des Cèdres
Cornebarrieu, France
Créteil - CHI
Créteil, 94000, France
Dax - CH
Dax, 40107, France
Denain - CH
Denain, France
Dijon - CAC
Dijon, 21000, France
Dijon - CHU
Dijon, 63000, France
Draguignan - CH
Draguignan, 83300, France
CH de Dreux
Dreux, France
Elbeuf - CH
Elbeuf, France
Ermont - Clinique Claude Bernard
Ermont, France
Epinal - CH
Épinal, 88021, France
Evreux - CH
Évreux, France
Flers - CH
Flers, France
CHICAS Site de Gap
Gap, France
CHRU Grenoble
Grenoble, France
Saint Omer - CHI
Helfaut, 62570, France
Jonzac - CH
Jonzac, 17500, France
La Roche Sur Yon - CH
La Roche-sur-Yon, 85925, France
Le Havre - HPE
Le Havre, 76700, France
Le Mans - Centre Hospitalier
Le Mans, 72000, France
Le Mans - Clinique Victor Hugo
Le Mans, France
CH Dr Schaffner de Lens
Lens, France
Liévin - polyclinique de Riaumont
Liévin, 62806, France
CHU (Hôpital Calmette) - Pneumologie
Lille, 59000, France
Lille - Hôpital Calmette
Lille, 59000, France
Limoges - Hôpital du Cluzeau
Limoges, 87042, France
CH de Longjumeau
Longjumeau, France
Lorient - CHBS
Lorient, France
Clinique des 4 Pavillons
Lormont, France
Lyon - Clinique Mutualiste
Lyon, 69003, France
Clinique Mutualiste Eugène André
Lyon, France
HIA Desgenettes
Lyon, France
Hôpital de la Croix Rousse
Lyon, France
Lyon - Hôpital Louis Pradel (Pneumologie)
Lyon, France
Mantes La Jolie - CH
Mantes-la-Jolie, 78200, France
Marseille - Hôpital Sainte Marguerite
Marseille, 13000, France
Marseille - CRLCC
Marseille, France
Polyclinique du Parc
Maubeuge, France
Meaux - CH
Meaux, 77100, France
Metz - CHR
Metz, 57000, France
Metz - Clinique Claude Bernard
Metz, 57000, France
Metz - Belle Isle
Metz, France
Mont de Marsan - CH
Mont-de-Marsan, 40000, France
Montpellier - Clinique Clémentville
Montpellier, 34070, France
Montpellier - CHRU
Montpellier, 34295, France
Moulins - CH
Moulins, 03000, France
Mulhouse - CH
Mulhouse, 68000, France
CHU Nancy
Nancy, France
Nancy - Polyclinique Gentilly
Nancy, France
Nanterre - CH
Nanterre, 92014, France
Nantes - Centre René Gauducheau
Nantes, 44805, France
Hôpital Laënnec - CHU de Nantes
Nantes, France
Narbonne - Polyclinique Le Languedoc
Narbonne, France
Neuilly - Hôpital Américain de Paris
Neuilly, 92200, France
Nevers - CH
Nevers, 58033, France
Nice - CAC
Nice, 06000, France
Nîmes - Clinique Valdegour
Nîmes, 30900, France
CHU
Nîmes, France
Orléans - CH
Orléans, 45000, France
Paris - Saint Louis
Paris, 75000, France
Paris - hôpital Saint-Antoine
Paris, 75012, France
GH Paris Saint-Joseph
Paris, France
Hôpital Bichat - Claude - Bernard
Paris, France
Hôpital du Val de Grâce
Paris, France
Hôpital Européen Georges Pompidou
Paris, France
Hôpital Tenon
Paris, France
Paris - Curie
Paris, France
Pau - CH
Pau, 64046, France
Perpignan - Centre Catalan d'Oncologie
Perpignan, 66000, France
Perpignan - Ch
Perpignan, 66046, France
CH de Périgueux
Périgueux, France
Lyon Sud
Pierre-Bénite, 69495, France
CHU
Poitiers, France
Pontoise - CH
Pontoise, France
Reims - CHU
Reims, 51092, France
Reims - CRLCC
Reims, France
Rennes - CHU
Rennes, 35033, France
CHG de Roanne
Roanne, France
Rodez - CH
Rodez, 12021, France
Roncq - Clinique Saint-Roch
Roncq, 59223, France
Roubaix - CH
Roubaix, 59100, France
Rouen - CHU
Rouen, 76000, France
Centre Frederic Joliot
Rouen, France
Saint Brieuc - CHG
Saint-Brieuc, 22000, France
Saint Nazaire - Centre Etienne Dolet
Saint-Nazaire, 44600, France
Saint-Nazaire - CH
Saint-Nazaire, France
Saint Priest en Jarez - ICL
Saint-Priest-en-Jarez, 42270, France
Saint Quentin - CH
Saint-Quentin, 02100, France
Saverne - CH
Saverne, France
Senlis - CH
Senlis, 60300, France
Saint-Malo - CH
St-Malo, 35403, France
Strasbourg - NHC
Strasbourg, 63000, France
Suresnes - Hopital Foch
Suresnes, 92151, France
Thonon les bains
Thonon-les-Bains, 74200, France
Toulon - CHI
Toulon, 83000, France
Toulon - HIA
Toulon, 83000, France
Clinique Saint Jean du Languedoc
Toulouse, France
Toulouse - CHU Larrey
Toulouse, France
Toulouse - Clinique Pasteur
Toulouse, France
Tours - CHU
Tours, 37000, France
Troyes - CH
Troyes, 10000, France
Valenciennes - Clinique
Valenciennes, 59304, France
Verdun - CHG
Verdun, France
Vesoul - CHI
Vesoul, 70000, France
CHI de la Haute-Saône - Pneumologie
Vesoul, France
Clinique Mutualiste Les Portes du Sud
Vénissieux, France
Vienne - CH
Vienne, 38200, France
Villejuif - Institut Gustave Roussy
Villejuif, 94800, France
Related Publications (10)
Blons H, Oudart JB, Merlio JP, Debieuvre D, de Fraipont F, Audigier-Valette C, Escande F, Hominal S, Bringuier PP, Fraboulet-Moreau S, Ouafik L, Moro-Sibilot D, Lemoine A, Langlais A, Missy P, Morin F, Souquet PJ, Barlesi F, Cadranel J, Beau-Faller M; French Cooperative Thoracic Intergroup (IFCT). PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project. Lung Cancer. 2021 Jan;151:69-75. doi: 10.1016/j.lungcan.2020.11.008. Epub 2020 Nov 13.
PMID: 33248711BACKGROUNDBeau-Faller M, Pencreach E, Leduc C, Blons H, Merlio JP, Bringuier PP, de Fraipont F, Escande F, Lemoine A, Ouafik L, Denis M, Hofman P, Lacave R, Melaabi S, Langlais A, Missy P, Morin F, Moro-Sibilot D, Barlesi F, Cadranel J; French Cooperative Thoracic Intergroup (IFCT). Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project. Lung Cancer. 2020 Feb;140:19-26. doi: 10.1016/j.lungcan.2019.10.013. Epub 2019 Nov 15.
PMID: 31841714BACKGROUNDLeduc C, Merlio JP, Besse B, Blons H, Debieuvre D, Bringuier PP, Monnet I, Rouquette I, Fraboulet-Moreau S, Lemoine A, Pouessel D, Mosser J, Vaylet F, Langlais A, Missy P, Morin F, Moro-Sibilot D, Cadranel J, Barlesi F, Beau-Faller M; French Cooperative Thoracic Intergroup (IFCT). Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program. Ann Oncol. 2017 Nov 1;28(11):2715-2724. doi: 10.1093/annonc/mdx404.
PMID: 28945865BACKGROUNDKembou Nzale S, Weeks WB, Ouafik L, Rouquette I, Beau-Faller M, Lemoine A, Bringuier PP, Le Coroller Soriano AG, Barlesi F, Ventelou B. Inequity in access to personalized medicine in France: Evidences from analysis of geo variations in the access to molecular profiling among advanced non-small-cell lung cancer patients: Results from the IFCT Biomarkers France Study. PLoS One. 2020 Jul 1;15(7):e0234387. doi: 10.1371/journal.pone.0234387. eCollection 2020.
PMID: 32609781BACKGROUNDMordant P MD, PhD, Brosseau S, Milleron B, Santelmo N, Fraboulet-Moreau S, Besse B, Langlais A, Gossot D, Thomas PA, Pujol JL, Ricordel C, Madelaine J, Lamy R, Audigier-Valette C, Missy P, Blons H, Barlesi F, Westeel V; French Cooperative Thoracic Intergroup (IFCT). Outcome of Patients With Resected Early-Stage Non-small Cell Lung Cancer and EGFR Mutations: Results From the IFCT Biomarkers France Study. Clin Lung Cancer. 2023 Jan;24(1):1-10. doi: 10.1016/j.cllc.2022.08.013. Epub 2022 Aug 29.
PMID: 36180314BACKGROUNDGuibert N, Barlesi F, Descourt R, Lena H, Besse B, Beau-Faller M, Mosser J, Pichon E, Merlio JP, Ouafik L, Guichard F, Mastroianni B, Moreau L, Wdowik A, Sabourin JC, Lemoine A, Missy P, Langlais A, Moro-Sibilot D, Mazieres J. Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France. J Thorac Oncol. 2017 Jun;12(6):963-973. doi: 10.1016/j.jtho.2017.02.001. Epub 2017 Feb 9.
PMID: 28189832BACKGROUNDCouraud S, Barlesi F, Fontaine-Deraluelle C, Debieuvre D, Merlio JP, Moreau L, Beau-Faller M, Veillon R, Mosser J, Al Freijat F, Bringuier PP, Lena H, Ouafik L, Westeel V, Morel A, Audigier-Valette C, Missy P, Langlais A, Morin F, Souquet PJ, Planchard D; Biomarkers France Contributors. Clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study. Eur J Cancer. 2019 Jul;116:86-97. doi: 10.1016/j.ejca.2019.04.016. Epub 2019 Jun 8.
PMID: 31181537BACKGROUNDRuppert AM, Beau-Faller M, Debieuvre D, Ouafik L, Westeel V, Rouquette I, Mazieres J, Bringuier PP, Monnet I, Escande F, Ricordel C, Merlio JP, Janicot H, Lemoine A, Foucher P, Poudenx M, Morin F, Langlais A, Souquet PJ, Barlesi F, Wislez M. Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancerologie Thoracique Biomarkers France Study by KRAS Mutation Subtypes. JTO Clin Res Rep. 2020 May 15;1(3):100052. doi: 10.1016/j.jtocrr.2020.100052. eCollection 2020 Sep.
PMID: 34589947BACKGROUNDTomasini P, Brosseau S, Mazieres J, Merlio JP, Beau-Faller M, Mosser J, Wislez M, Ouafik L, Besse B, Rouquette I, Debieuvre D, Escande F, Westeel V, Audigier-Valette C, Missy P, Langlais A, Morin F, Moro-Sibilot D, Zalcman G, Barlesi F. EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice. Eur Respir J. 2017 Aug 10;50(2):1700514. doi: 10.1183/13993003.00514-2017. Print 2017 Aug.
PMID: 28798090BACKGROUNDBarlesi F, Mazieres J, Merlio JP, Debieuvre D, Mosser J, Lena H, Ouafik L, Besse B, Rouquette I, Westeel V, Escande F, Monnet I, Lemoine A, Veillon R, Blons H, Audigier-Valette C, Bringuier PP, Lamy R, Beau-Faller M, Pujol JL, Sabourin JC, Penault-Llorca F, Denis MG, Lantuejoul S, Morin F, Tran Q, Missy P, Langlais A, Milleron B, Cadranel J, Soria JC, Zalcman G; Biomarkers France contributors. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet. 2016 Apr 2;387(10026):1415-1426. doi: 10.1016/S0140-6736(16)00004-0. Epub 2016 Jan 15.
PMID: 26777916RESULT
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Fabrice Barlesi, PhD, MD
IFCT, Aix Marseille Université / Assistance Publique Hôpitaux de Marseille
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 1, 2012
First Posted
October 4, 2012
Study Start
April 1, 2012
Primary Completion
April 1, 2013
Study Completion
April 1, 2013
Last Updated
July 21, 2023
Record last verified: 2023-07
Data Sharing
- IPD Sharing
- Will not share